Multiple Myeloma Patients Had Continued Response to ASCT Past 100-Day Disease Assessment
Patients with multiple myeloma who underwent autologous stem cell transplantation may have a continued response to the treatment even after the traditional disease assessment at 100 days. A new study indicates that this continued response maintained prognostic value and should be taken into account when considering post-transplant therapies.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Myeloma | Stem Cell Therapy | Stem Cells | Study | Transplants